AvenCell
AvenCell develops next generation immunotherapies against hard-to-treat blood and solid tumor cancers.
HQ location
Cambridge, United States
Website
Enterprise value
$448—672m
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $112m | Series B | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads